Testosterone deficiency in both men and women produces fatigue, cognitive decline, loss of lean mass, increased adiposity, low libido, and mood instability. Intramuscular testosterone cypionate provides stable, predictable pharmacokinetics and is the most clinically controllable delivery method. Topical formulations are appropriate for certain clinical profiles. For men concerned with fertility, fertility-sparing protocols using hCG and/or enclomiphene preserve testicular function while addressing symptomatic deficiency. All protocols are monitored with serial labs including free testosterone, estradiol, hematocrit, and PSA.

Estradiol is the dominant estrogen in premenopausal women and a critical hormone in men at physiologic levels. In women, estrogen replacement addresses vasomotor symptoms, bone density loss, urogenital atrophy, cardiovascular risk, and cognitive protection. Topical transdermal delivery bypasses first-pass hepatic metabolism avoiding the clotting risk associated with oral estrogens. Dosing is individualized based on symptom burden, lab values, and risk profile.

Bioidentical progesterone is used in women to oppose estrogen in the uterine lining, support luteal phase adequacy, and address sleep disruption, anxiety, and mood instability. Unlike synthetic progestins, bioidentical progesterone does not carry the adverse cardiovascular and breast risk profile of older synthetic agents. Topical delivery is preferred for neurological and sleep-related effects.

Levothyroxine is synthetic T4 the storage form of thyroid hormone requiring peripheral conversion to active T3. Appropriate for patients with adequate conversion capacity and normal RT3. Dosing is titrated against Free T4, Free T3, and clinical response not TSH alone.

Liothyronine is active T3 directly activating thyroid receptors at the cellular level. Used when T4 monotherapy fails to resolve symptoms despite normalized TSH, or when elevated Reverse T3 indicates impaired conversion. Often combined with T4 to replicate the full spectrum of thyroid output.

NDT (including Armour Thyroid and NP Thyroid) is derived from porcine thyroid gland and contains both T4 and T3 in a fixed 4:1 ratio. Some patients respond better to NDT than synthetic monotherapy particularly those with persistent fatigue, brain fog, or weight resistance on T4 alone.

Compounded thyroid formulations allow precise individualization of T4 and T3 ratios, bypassing the fixed ratio limitations of NDT. Sustained-release T3 compounding blunts peak-trough fluctuation. Sourced from licensed US pharmacies with documented quality standards.

DHEA-S declines by roughly 80% between ages 25 and 75 correlating with increased all-cause mortality, immune senescence, and reduced androgenic tone. Supplemental DHEA serves as a precursor to both testosterone and estrogen, providing substrate for downstream synthesis without directly replacing end-hormones. In women, topical vaginal DHEA addresses urogenital atrophy with minimal systemic absorption. Oral dosing is guided by serum DHEA-S levels.

GH secretagogues stimulate the pituitary to release growth hormone through its natural pulsatile pattern rather than replacing GH exogenously, which suppresses endogenous production and disrupts feedback regulation. Results include improved IGF-1, preserved lean mass, accelerated tissue repair, improved sleep architecture, and reduction in visceral adiposity. IGF-1 is monitored serially to maintain optimal physiologic range.

GLP-1 receptor agonists mimic the incretin hormone GLP-1, produced naturally in the gut after eating. They reduce appetite through hypothalamic signaling, slow gastric emptying, enhance glucose-dependent insulin secretion, and suppress glucagon. Beyond glycemic control, this class demonstrates significant cardiovascular benefit and reduction in visceral adiposity. Used as a metabolic reset tool in combination with dietary restructuring, resistance training, and hormonal optimization not as a standalone indefinite intervention.

Select oral hypoglycemics are used in specific clinical contexts based on mechanism of action and secondary benefits. Metformin the most studied longevity compound in clinical medicine activates AMPK, reduces hepatic glucose output, and has demonstrated anti-aging effects in multiple model systems including the TAME trial. All interventions are monitored with serial metabolic panels, fasting insulin, and HbA1c.

Methylcobalamin is the active, methylated form of B12 directly usable without conversion. Preferred for neurological applications and patients with MTHFR variants. Intramuscular delivery bypasses gastrointestinal absorption entirely critical for patients with low intrinsic factor, gastric atrophy, or chronic PPI use. Used to correct deficiency and reduce elevated homocysteine.

5-MTHF is the biologically active form of folate. Approximately 40% of the population carries MTHFR variants that reduce conversion of dietary folate by 30 - 70% rendering folic acid supplementation inadequate. 5-MTHF provides the methyl donor directly, supporting DNA synthesis, homocysteine remethylation, and neurotransmitter production.

P5P is the active coenzyme form of B6 required for over 100 enzymatic reactions including homocysteine transsulfuration, neurotransmitter synthesis (serotonin, dopamine, GABA), and heme production. Standard pyridoxine requires hepatic conversion to P5P a step impaired in some individuals.

TMG donates methyl groups directly to homocysteine via the BHMT pathway a folate-independent remethylation route. Particularly valuable in patients with significant MTHFR impairment. Also supports liver function and has shown benefit in reducing hepatic fat accumulation.

Peptides are short-chain amino acid sequences that act as precise biological signals binding specific receptors to initiate targeted physiologic responses including tissue repair, immune modulation, gut integrity, metabolic regulation, and hormonal signaling. All peptides are sourced from licensed US compounding pharmacies and subject to third-party certificates of analysis verifying identity, purity, and sterility.

GHK-Cu (copper tripeptide-1) is a naturally occurring human plasma peptide that stimulates collagen and elastin synthesis, activates antioxidant enzymes, promotes angiogenesis in healing tissue, and downregulates genes associated with tissue destruction. Used for collagen stimulation, skin laxity, fine line reduction, and post-procedure recovery the mechanistic intersection of regenerative and aesthetic medicine.

The comprehensive panel frequently reveals deficiencies or risk signals outside the primary protocol categories. These are addressed with targeted interventions selected on mechanistic grounds not by algorithm or template. Every adjunct has a defined biomarker target, a mechanism of action, and a monitoring endpoint. Nothing is prescribed indefinitely without objective justification.